We would like to thank those who found the time to come to Madrid to join us at our 7th Annual Pricing, Reimbursement and Market Access in Pharma conference– to our partners and sponsors for supporting us and the whole event, our speakers and advisers for contributing with their valuable knowledge and experiences, and all the delegates for choosing our event.
If you have any further questions or you are just eager to learn more about our upcoming events, do not hesitate to
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
. We would also appreciate your comments and suggestions that could help us improve our future conferences.
Thank you for your support and contribution,
we look forward to seeing you again next year!
we look forward to seeing you again next year!
“The conference was very informative and expertly organized with a good range of speakers.”
Sarah Garner, NICE, UK1
Given its complex geo-political situation, position in the global economy and number of voices to be heard, market access in Europe brings challenges and hurdles on one hand and great potential on the other.
How successful are you in managing increasingly complex Market Access environment?
Benchmark the recent policy developments & changes in healthcare systems across major European markets to ensure better access of patients to new drugs. Following six successful annuals, Fleming Europe invites you to the 7th Annual Pricing, Reimbursement & Market Access in Pharma. Yet again we have gathered worldwide Pharmaceutical pricing specialists who will share their knowledge with you. You will have the chance to meet true market leaders, top speakers and real experts from pharmaceutical industry.
FIND YOUR REASON TO ATTEND
- Reveal how to develop an effective strategy to succeed in country-specific negotiations for price approval and granting of reimbursement
- Explore the concept of risk-sharing to accelerate the market access
- Gain critical insights into HTAs & their role in assessments of new drugs
- Understand how to deal with the increasing complexity and uncertainty in current pricing & reimbursement environment
- Reveal cost-effectiveness measures & the impact on the industry – is the innovation rewarded correctly?
- Make market access an integral part of the company & incorporate market access into the entire drug’s life cycle
- How can interaction between regulators and payers facilitate access to orphan drugs?
- Discover the role of HTAs – the importance of early dialogue with HTA agencies
WHO SHOULD ATTEND
Senior Vice Presidents, Vice Presidents, Senior Executives, Global Heads, Heads, Directors, Senior Managers, Managers of:
- Pricing, Reimbursement, Market Access, Commercial Pricing Pricing Strategists, Health Economics, Outcomes Research, Regulatory Affairs, Governmental Affairs, Public Affairs, Public Policy Directors, Operations, Governmental bodies, Regulatory bodies
